The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Acerta Pharma competitive analysis

Loading summary...

Latest patents of Acerta Pharma opposed by its competitors

Explore Acerta Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3954690
Apr 5, 2023Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide1
EP3179991
Oct 6, 2021Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor1
EP3317281
Apr 22, 2020Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1 -(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide1

Latest PTAB cases involving Acerta Pharma

Discover the latest PTAB cases involving Acerta Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 15, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Acerta Pharma

IPR2023-00478Feb 3, 2023SANDOZACERTA PHARMAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Acerta Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ACERTA PHARMA - 3 - 1
KRAUS & LEDERER PARTGMBB68 - - -
SANDOZ1191619 -
STADA ARZNEIMITTEL11028 - -